Figure 1. Administration of MCC950 modulates survival and reduces airway inflammation during IAV- infection.

Groups of wild-type C57BL/6 mice were infected intranasally with (a/d) low dose (10²PFU) (n = 5/group) or (b/c/e/f) high dose (n = 10 per group) HKx31 (10⁵PFU). Mice were treated intranasally with MCC950 (5 mg/kg) at indicated time points following infection (arrows). Uninfected mice treated with MCC950 are included for comparison. (a–c) Survival curves are shown. ***P < 0.001, Mantel–Cox log-rank test. (d–f) Mice were weighed daily and resulted expressed as mean percent weight change. (g–p) Mice (n = 5 mice/group) were treated with MCC950 on day 3 following high dose HKx31 infection and 24 hours later (g,h) total numbers of leukocytes in BAL were determined by viable cell counts and Ly6G⁺ neutrophils, total CD11c⁺ MHC Class II^lo macrophages and Ly6C⁺ inflammatory macrophages in BAL were determined by flow cytometry. Pro-inflammatory cytokine levels were determined by ELISA or CBA in (i–m) BAL fluid and (n,o) sera. Data presented is mean ± SEM from 5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA. (p) Viral loads in the lung and nasal tissues by standard plaque assay.